Wolfe Research Lowers Celldex Therapeutics (NASDAQ:CLDX) to Peer Perform

Wolfe Research cut shares of Celldex Therapeutics (NASDAQ:CLDX) from an outperform rating to a peer perform rating in a report issued on Friday morning, Marketbeat reports.

Several other equities analysts also recently commented on the company. HC Wainwright restated a buy rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research report on Thursday. Cantor Fitzgerald reissued an overweight rating and issued a $67.00 price target on shares of Celldex Therapeutics in a report on Monday, September 16th. Wells Fargo & Company raised shares of Celldex Therapeutics from a hold rating to a strong-buy rating in a report on Thursday. Finally, Stifel Nicolaus initiated coverage on shares of Celldex Therapeutics in a research report on Tuesday, June 18th. They set a buy rating and a $58.00 target price for the company. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Celldex Therapeutics currently has an average rating of Buy and an average target price of $63.83.

Celldex Therapeutics Trading Up 1.0 %

Shares of NASDAQ:CLDX opened at $33.20 on Friday. The stock has a 50 day moving average of $38.35 and a 200 day moving average of $38.29. The company has a market cap of $2.19 billion, a PE ratio of -11.65 and a beta of 1.56. Celldex Therapeutics has a 12-month low of $22.11 and a 12-month high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.05. Celldex Therapeutics had a negative net margin of 1,809.18% and a negative return on equity of 23.66%. The firm had revenue of $2.50 million during the quarter, compared to analysts’ expectations of $1.13 million. Equities research analysts predict that Celldex Therapeutics will post -2.5 earnings per share for the current fiscal year.

Institutional Trading of Celldex Therapeutics

Large investors have recently made changes to their positions in the business. Wellington Management Group LLP grew its position in Celldex Therapeutics by 19.2% in the fourth quarter. Wellington Management Group LLP now owns 6,476,561 shares of the biopharmaceutical company’s stock worth $256,860,000 after acquiring an additional 1,044,728 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Celldex Therapeutics by 19.8% during the 1st quarter. Vanguard Group Inc. now owns 3,650,582 shares of the biopharmaceutical company’s stock valued at $153,215,000 after purchasing an additional 604,251 shares during the last quarter. Eventide Asset Management LLC raised its holdings in Celldex Therapeutics by 126.9% during the 4th quarter. Eventide Asset Management LLC now owns 3,630,013 shares of the biopharmaceutical company’s stock valued at $143,966,000 after buying an additional 2,030,013 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Celldex Therapeutics by 631.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company’s stock worth $129,571,000 after buying an additional 2,664,915 shares during the last quarter. Finally, Bellevue Group AG boosted its stake in Celldex Therapeutics by 15.7% during the first quarter. Bellevue Group AG now owns 2,796,615 shares of the biopharmaceutical company’s stock worth $117,374,000 after buying an additional 380,319 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.